RxDoctor Payments DataLook up a doctor →

Michael Gen, MD

Interventional Cardiology · Virginia Beach, VANPI 1487623906

Payments from drug & device makers

$221,524in general payments, 2019–2025

Across 1,071 payments — averaging $206.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$141K
  • Lundbeck LLC$30K
  • Novartis$23K
  • AstraZeneca$7K
  • Medtronic$3K
  • Abbott$2K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$9,4205%
  • Speaking & faculty fees$144,27270%
  • Travel & lodging$25,03412%
  • Food & beverage$27,93514%
  • Education$2030%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$221,524 in reported general payments places this provider in the 90th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$977,292
Medicare patients
1,253
Services billed
7,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndaqelTafamidis Meglumine14$450,264
VyndamaxTafamidis20$443,296
EliquisApixaban326$371,078
EntrestoSacubitril/Valsartan146$179,363
Repatha SureclickEvolocumab127$144,747
FarxigaDapagliflozin Propanediol129$140,507
AdempasRiociguat13$114,091
XareltoRivaroxaban48$60,182
BrilintaTicagrelor45$36,438
VascepaIcosapent Ethyl60$35,366
JardianceEmpagliflozin30$26,644
OzempicSemaglutide12$18,417
Repatha SyringeEvolocumab23$14,789
VerquvoVericiguat12$14,168
Praluent PenAlirocumab20$12,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndaqel, Vyndamax, Eliquis$815$1,264,638360 claims
NovartisEntresto$23,059$179,363146 claims
AstraZenecaFarxiga, Brilinta$6,525$176,945174 claims
BayerAdempas$511$114,09113 claims
Johnson & JohnsonXarelto$687$60,18248 claims
Boehringer IngelheimJardiance$454$26,64430 claims
Novo NordiskOzempic$166$18,41712 claims
MerckVerquvo$360$14,16812 claims
Esperion Therapeutics, Inc.Nexletol$193$7,75113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →